Literature DB >> 2164444

Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix.

B P Negrini1, M H Schiffman, R J Kurman, W Barnes, L Lannom, K Malley, L A Brinton, G Delgado, S Jones, J G Tchabo.   

Abstract

Oral contraceptive (OC) use was examined as a risk factor for cytological abnormalities of the cervix among 1964 women receiving Papanicolaou smears at three hospitals in the Washington, D.C., area. A single pathologist classified cytological results from all women as normal (n = 1423), atypia (n = 314), low grade squamous intraepithelial lesion (SIL; n = 208), or high grade SIL (n = 19). Women in each of the three abnormal groups were compared to women with normal cytological diagnoses. A subset of 579 patients, including most of the women with low or high grade SIL and a matched group of controls, was tested for human papillomavirus (HPV) by type-specific Southern blot hybridization to examine the effects of OC use while taking into account the effects of HPV infection. OC use was found to be unrelated to risk of atypia or low grade SIL but was associated with an elevated risk of high grade SIL that increased with longer duration of use (relative risk = 4.6, 95% confidence interval = 1.1-18.1 for greater than or equal to 5 years of use). HPV infection was associated, as expected, with risk of low and high grade SIL but not with atypia. Taking the HPV results into consideration did not alter the OC findings. There was no evidence that OC use synergistically increased the risk of cervical neoplasia among HPV-infected women, although small numbers prevented a reliable evaluation for high grade SIL. OC use did appear to increase the detection of HPV types 16/18, but the etiological importance of this finding is unclear.

Entities:  

Keywords:  Biology; Cervix--changes; Clinical Research; Contraception; Contraceptive Methods; Cytologic Effects; Diseases; Examinations And Diagnoses; Family Planning; Genitalia; Genitalia, Female; Incidence; Laboratory Examinations And Diagnoses; Measurement; Oral Contraceptives; Physiology; Research Methodology; Risk Factors; Urogenital System; Uterus; Viral Diseases

Mesh:

Substances:

Year:  1990        PMID: 2164444

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Is oral contraceptive associated with genital warts?

Authors:  J D Ross
Journal:  Genitourin Med       Date:  1996-10

2.  Oral contraceptive use and human papillomavirus infection in women without abnormal cytological results.

Authors:  G Veress; T Csiky-Mészáros; J Czeglédy; L Gergely
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

3.  Detection of human papillomavirus in cervical scrapings by in situ hybridization and the polymerase chain reaction in relation to cytology.

Authors:  M Ramael; K Segers; N Pannemans; F Wesling; E Van Marck
Journal:  Histochem J       Date:  1995-01

4.  Efficacy trial of topically administered interferon gamma-1 beta gel in comparison to laser treatment in cervical intraepithelial neoplasia.

Authors:  A Schneider; T Grubert; R Kirchmayr; D Wagner; U Papendick; G Schlunck
Journal:  Arch Gynecol Obstet       Date:  1995       Impact factor: 2.344

Review 5.  Influence of ovarian hormones on urogenital infection.

Authors:  C Sonnex
Journal:  Sex Transm Infect       Date:  1998-02       Impact factor: 3.519

6.  The combined influence of oral contraceptives and human papillomavirus virus on cutaneous squamous cell carcinoma.

Authors:  Jimmy T Efird; Amanda E Toland; C Suzanne Lea; Christopher J Phillips
Journal:  Clin Med Insights Oncol       Date:  2011-03-27

7.  Does oral contraceptive pill increase the risk of abnormal Pap smear?

Authors:  Fariba Binesh; Ali Akhavan; Azar Pirdehghan; Mahnoosh Davoodi
Journal:  Iran J Reprod Med       Date:  2013-09

8.  Oral contraceptives and cervical cancer--further findings from the Oxford Family Planning Association contraceptive study.

Authors:  K T Zondervan; L M Carpenter; R Painter; M P Vessey
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.